Loading
Life sciences · Journal article
Frontiers in Pharmacology · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Perilla frutescens, an edible medicinal plant from East Asia, produces diverse bioactive phytochemicals with anticancer activity, including perillaldehyde (PAH), rosmarinic acid (RA), luteolin, apigenin, and alpha-linolenic acid (ALA). These compounds exert multi-target anticancer effects through apoptosis, autophagy, and ferroptosis. PAH triggers ferroptosis in gastric cancer via the System Xc-/GSH/GPX4 axis and P62-Keap1-Nrf2 pathway, while inducing protective autophagy in colorectal cancer through SRD5A1 and PI3K/AKT modulation. RA directly binds KRAS(G12C) and suppresses NSCLC via KRAS/AKT/ERK, and inhibits stress-induced TNBC metastasis through Src inactivation. Perilla leaf extracts activate Hippo-YAP/TAZ signaling in breast cancer. ALA-rich perilla seed oil (PSO) mitigates tumorigenesis in colitis-associated colorectal cancer models and restores gut microbial homeostasis. This review synthesizes current molecular evidence on perilla compounds in cancer therapy, focusing on apoptosis-autophagy-ferroptosis crosstalk. The multi-target characteristics position perilla-derived compounds as adjuvant cancer therapy candidates, though bioavailability and clinical translation still challenges remain.